In today’s briefing:
- Taisho Pharmaceutical (4581 JP): A Compelling Play on Japan’s Consumer Spending Recovery
Taisho Pharmaceutical (4581 JP): A Compelling Play on Japan’s Consumer Spending Recovery
- Taisho Pharmaceutical Holdin (4581 JP) is the leader in the Japanese OTC drug market. The company’s Lipovitan, Pabron and RiUP brands capture top market share in their respective categories.
- With the re-opening of economy, increasing number of people are indulging in outdoor activities and consumer spending is recovering. These should boost Taisho’s OTC drug business.
- The company’s prescription pharmaceutical business is well-positioned for long-term growth, driven by strong performance of existing drugs and upcoming new product launch.
Before it’s here, it’s on Smartkarma
